Cargando…

Bevacizumab in ovarian cancer: A critical review of phase III studies

Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian cancer (OC). Randomized Phase III trials evaluated the combination of BV plus standard chemotherapy for first-line tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossi, Luigi, Verrico, Monica, Zaccarelli, Eleonora, Papa, Anselmo, Colonna, Maria, Strudel, Martina, Vici, Patrizia, Bianco, Vincenzo, Tomao, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355353/ https://www.ncbi.nlm.nih.gov/pubmed/27852039 http://dx.doi.org/10.18632/oncotarget.13310

Ejemplares similares

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach
por: Tomao, Federica, et al.
Publicado: (2013)

Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013)

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
por: Papa, Anselmo, et al.
Publicado: (2016)

Triple-negative breast cancer: new perspectives for targeted therapies
por: Tomao, Federica, et al.
Publicado: (2015)

Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases
por: Rossi, Luigi, et al.
Publicado: (2012)

Investigating Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells
por: Tomao, Federica, et al.
Publicado: (2014)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
por: Rossi, Luigi, et al.
Publicado: (2013)

Fertility drugs, reproductive strategies and ovarian cancer risk
por: Tomao, Federica, et al.
Publicado: (2014)

Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation
por: Rossi, Luigi, et al.
Publicado: (2013)

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
por: Rossi, Luigi, et al.
Publicado: (2013)

Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration
por: Giovannoni, Sara, et al.
Publicado: (2014)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

An unusual case of spleen metastasis from carcinoma ex pleomorphic adenoma of the parotid gland
por: Rossi, Luigi, et al.
Publicado: (2014)

Breast cancer metastatic to the pituitary gland: a case report
por: Spinelli, Gian Paolo, et al.
Publicado: (2012)

Critical appraisal of bevacizumab in the treatment of ovarian cancer
por: Yoshida, Hiroyuki, et al.
Publicado: (2015)

Immunologic treatments for precancerous lesions and uterine cervical cancer
por: Vici, Patrizia, et al.
Publicado: (2014)

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials
por: Marchetti, Claudia, et al.
Publicado: (2015)

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
por: Arrivi, Giulia, et al.
Publicado: (2022)

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
por: Mazzotta, Marco, et al.
Publicado: (2019)

Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis
por: Zhou, Mingyi, et al.
Publicado: (2013)

Bevacizumab in the treatment of ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2011)

Emerging Biological Treatments for Uterine Cervical Carcinoma
por: Vici, Patrizia, et al.
Publicado: (2014)

ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies
por: Colombo, Ilaria, et al.
Publicado: (2020)

Subcutaneous metastases from colon cancer: a case report
por: Lo Russo, Giuseppe, et al.
Publicado: (2012)

Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature
por: Turco, Luigi Carlo, et al.
Publicado: (2020)

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
por: Colombo, Nicoletta, et al.
Publicado: (2019)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Safety Analysis of Bevacizumab in Ovarian Cancer Patients
por: Wang, Yingwen, et al.
Publicado: (2023)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Positron Emission Tomography (PET) radiotracers in oncology – utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC)
por: Miele, Evelina, et al.
Publicado: (2008)

Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2016)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
por: Palaia, Innocenza, et al.
Publicado: (2020)

The synchronous occurrence of squamous cell carcinoma and gastrointestinal stromal tumor (GIST) at esophageal site
por: Spinelli, Gian Paolo, et al.
Publicado: (2008)

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
por: Rossari, José R., et al.
Publicado: (2012)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9aeu3mm4dq3mn75djkp2cec237